Zacks Research Has Positive Estimate for Biogen Q4 Earnings

Biogen Inc. (NASDAQ:BIIB) – Equities research analysts at Zacks Research boosted their Q4 2025 earnings per share (EPS) estimates for Biogen in a research note issued to investors on Thursday, January 15th. Zacks Research analyst Team now anticipates that the biotechnology company will earn $1.49 per share for the quarter, up from their previous forecast of $1.48. The consensus estimate for Biogen’s current full-year earnings is $15.83 per share.

A number of other analysts also recently weighed in on BIIB. Weiss Ratings restated a “hold (c-)” rating on shares of Biogen in a report on Monday, December 29th. Guggenheim upped their price target on Biogen from $165.00 to $185.00 in a research report on Friday, October 31st. Needham & Company LLC restated a “hold” rating on shares of Biogen in a research report on Wednesday, September 24th. Tudor Pickering set a $157.00 price objective on Biogen in a research note on Monday, November 3rd. Finally, Robert W. Baird reduced their target price on Biogen from $255.00 to $250.00 in a report on Friday, October 31st. Ten equities research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $190.50.

Biogen Price Performance

BIIB stock opened at $164.42 on Monday. The company has a market capitalization of $24.12 billion, a P/E ratio of 14.99, a PEG ratio of 1.37 and a beta of 0.13. The company has a fifty day moving average price of $175.04 and a 200-day moving average price of $152.14. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.04 and a current ratio of 2.72. Biogen has a 52-week low of $110.04 and a 52-week high of $190.20.

Biogen (NASDAQ:BIIB) last posted its earnings results on Thursday, October 30th. The biotechnology company reported $4.81 EPS for the quarter, topping the consensus estimate of $3.89 by $0.92. Biogen had a net margin of 15.98% and a return on equity of 14.13%. The business had revenue of $2.53 billion for the quarter, compared to the consensus estimate of $2.34 billion. During the same period last year, the company earned $4.08 EPS. The firm’s revenue was up 2.8% compared to the same quarter last year. Biogen has set its FY 2025 guidance at 14.500-15.00 EPS.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Advisory Services Network LLC lifted its position in shares of Biogen by 3.9% in the third quarter. Advisory Services Network LLC now owns 1,792 shares of the biotechnology company’s stock valued at $251,000 after acquiring an additional 68 shares in the last quarter. CVA Family Office LLC increased its position in shares of Biogen by 18.1% during the third quarter. CVA Family Office LLC now owns 464 shares of the biotechnology company’s stock worth $65,000 after purchasing an additional 71 shares in the last quarter. Davis Investment Partners LLC raised its stake in Biogen by 1.7% in the 4th quarter. Davis Investment Partners LLC now owns 4,374 shares of the biotechnology company’s stock valued at $778,000 after purchasing an additional 71 shares during the last quarter. TD Private Client Wealth LLC raised its stake in Biogen by 22.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 414 shares of the biotechnology company’s stock valued at $58,000 after purchasing an additional 76 shares during the last quarter. Finally, Wedmont Private Capital lifted its holdings in Biogen by 3.8% in the 2nd quarter. Wedmont Private Capital now owns 2,190 shares of the biotechnology company’s stock valued at $291,000 after purchasing an additional 81 shares in the last quarter. 87.93% of the stock is owned by institutional investors.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.